(Q24202970)

PubMed

26 October 2023

3

R Andrew Moore

R Andrew

Moore

1 reference

PubMed

26 October 2023

Simon Law

1

Simon

Law

1 reference

PubMed

24142431

Cochrane Database of Systematic Reviews

26 October 2023

publication date

21 October 2013

0 references

published in

0 references

cites work

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Sumatriptan and naproxen sodium for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Fixed-dose Sumatriptan/Naproxen Sodium Compared with each Monotherapy Utilizing the Novel Composite Endpoint of Sustained Pain-free/no Adverse Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The prevalence of primary headache disorders in Russia: a countrywide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Deconstructing migraine headache into peripheral and central sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The visual analogue pain intensity scale: what is moderate pain in millimetres?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The International Classification of Headache Disorders, 3rd edition (beta version)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Naproxen with or without an antiemetic for acute migraine headaches in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The cost of headache disorders in Europe: the Eurolight project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Migraine prevalence, disease burden, and the need for preventive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Prevalence and burden of headache and migraine in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Migraine: the seventh disabler

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Prevalence of headache in Europe: a review for the Eurolight project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Impact of covert duplicate publication on meta-analysis: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Migraine prevalence by age and sex in the United States: a life-span study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

The prevalence and burden of primary headaches in China: a population-based door-to-door survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

7 January 2021

Guidelines for controlled trials of drugs in migraine: second edition

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

7 January 2021

Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

7 January 2021

Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

7 January 2021

Naproxen sodium decreases migraine recurrence when administered with sumatriptan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008541.PUB2

7 January 2021

10.1002/14651858.CD008541.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_2cvb4dzm2velbnbc7rzdchqthe

0 references